Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01742221Phase 1Completed

Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

Role: lead

NCT02343133Phase 2Completed

Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome

Role: lead

NCT02544061Phase 2Completed

NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds

Role: lead

NCT02542124Phase 2Unknown

NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

Role: lead

NCT02544724Phase 2Unknown

NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy

Role: lead

All 5 trials loaded